Study supports monovalent antibody in neuropsychiatric disease
New preclinical data have demonstrated that Arialys Therapeutics’ lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioural symptoms in a non-human primate model.
The company says the findings support the continued clinical development of ART5803 as a first-in-class, targeted therapeutic.
Arialys is currently completing Phase I safety studies for ART5803 and plans Phase II evaluation in ANRE and autoimmune psychosis patients in the second half of 2025.
“These data provide compelling evidence that ART5803 can directly block the pathogenic effect of autoantibodies that target the NMDA receptor, resulting in a rapid resolution of symptoms,” said Mitsuyuki Matsumoto, Chief Scientific Officer of Arialys Therapeutics and senior author of the paper.
“Our detailed structural and functional analyses confirm that ART5803 precisely inhibits NMDA receptor internalisation induced by the pathogenic autoantibodies, while preserving normal receptor function. In addition, our discovery of a potential molecular mimicry mechanism for anti-NMDA receptor autoantibody generation broadens the understanding of disease initiation and may inform future indication expansion for ART5803.”
Opportunity in autoimmune neuropsychiatric disorders
ANRE is a rare, potentially lethal, poorly managed, and often misdiagnosed neurological disease. It is caused by pathogenic autoantibodies that bind to and crosslink NMDA receptors in the brain, leading to receptor internalisation and synaptic dysfunction.
Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia.
ART5803 is a humanised, monovalent IgG1 antibody engineered to selectively bind the GluN1 subunit of the NMDA receptor without disrupting receptor function or causing internalisation.
In this study, ART5803 demonstrated the ability to potently block NMDA receptor internalisation in cellular and neuronal models and reversed both molecular and behavioural hallmarks of disease in a novel marmoset model of ANRE.
In addition to demonstrating the therapeutic potential of ART5803, the study revealed a potential link between infections – specifically Toxoplasma gondii and certain bacterial pathogens – and the generation of pathogenic anti-NMDA receptor autoantibodies. Toxoplasmosis and bacterial infections are well-established risk factors for a range of neuropsychiatric conditions.
The authors conclude that the findings support broader therapeutic opportunities for ART5803 across autoimmune neuropsychiatric disorders.
Diana Spencer, Senior Digital Content Editor, DDW
